Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (P...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Karger Publishers 2024-06-01
Reeks:	Liver Cancer
Online toegang:	https://beta.karger.com/Article/FullText/539897
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!